These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10029599)

  • 1. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
    Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
    Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
    Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RG; Croucher PI
    Br J Haematol; 2000 Oct; 111(1):283-6. PubMed ID: 11091214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
    Cruz JC; Alsina M; Craig F; Yoneda T; Anderson JL; Dallas M; Roodman GD
    Exp Hematol; 2001 Apr; 29(4):441-7. PubMed ID: 11301184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
    Geng CJ; Liang Q; Zhong JH; Zhu M; Meng FY; Wu N; Liang R; Yuan BY
    BMJ Open; 2015 Jun; 5(6):e007258. PubMed ID: 26038356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
    Halvorson KG; Sevcik MA; Ghilardi JR; Sullivan LJ; Koewler NJ; Bauss F; Mantyh PW
    J Pain Symptom Manage; 2008 Sep; 36(3):289-303. PubMed ID: 18411018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate in metastatic bone disease: a review of preclinical data.
    Bauss F; Body JJ
    Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.
    Radl J; Croese JW; Zurcher C; van den Enden-Vieveen MH; Brondijk RJ; Kazil M; Haaijman JJ; Reitsma PH; Bijvoet OL
    Cancer; 1985 Mar; 55(5):1030-40. PubMed ID: 3967188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates--mechanisms of action in multiple myeloma.
    Shipman CM; Rogers MJ; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher PI
    Acta Oncol; 2000; 39(7):829-35. PubMed ID: 11145441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ibandronate: keep life in motion].
    Longo F; Mansueto G
    Tumori; 2004; 90(2):9-16. PubMed ID: 15237599
    [No Abstract]   [Full Text] [Related]  

  • 18. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
    Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
    Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.